OptiNose (OPTN) to Release Quarterly Earnings on Thursday

OptiNose (NASDAQ:OPTNGet Free Report) is anticipated to release its earnings data before the market opens on Thursday, March 20th. Analysts expect OptiNose to post earnings of ($0.67) per share and revenue of $21.02 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

OptiNose Trading Up 9.7 %

OptiNose stock opened at $5.88 on Tuesday. OptiNose has a 1-year low of $4.82 and a 1-year high of $31.50. The firm has a market capitalization of $59.15 million, a price-to-earnings ratio of -1.40 and a beta of -0.30. The firm’s fifty day moving average price is $5.80 and its two-hundred day moving average price is $8.30.

Wall Street Analysts Forecast Growth

OPTN has been the topic of a number of recent analyst reports. Lake Street Capital dropped their price target on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. HC Wainwright raised their price target on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, January 3rd.

Read Our Latest Stock Analysis on OptiNose

Insiders Place Their Bets

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.30% of the company’s stock.

OptiNose Company Profile

(Get Free Report)

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

Further Reading

Earnings History for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.